期刊文献+

双歧杆菌三联活菌胶囊对进展期胃癌术后化疗患者化疗副作用及肠道菌群的影响 被引量:26

Effect of Bifid Triple Viable capsules on side effects of chemotherapy and intestinal flora in patients with advanced gastric cancer after postoperative chemotherapy
原文传递
导出
摘要 目的探讨口服双歧杆菌三联活菌胶囊(BTVC)对进展期胃癌术后化疗患者的化疗副作用及肠道菌群影响。方法选取铜陵市人民医院2016年2月至2017年1月收治的根治性胃癌术后首次化疗患者为研究对象,随机分成奥沙利铂+替吉奥联合化疗方案组32例(对照组),奥沙利铂+卡培他滨+BTVC联合治疗组26例(观察组)。检测两组患者肠道菌群变化及记录患者不良反应情况。结果治疗后对照组中白细胞<3×109/L、粒细胞<2×109/L、血红蛋白<110g/L、血小板<100×109/L、肝功能损害、周围神经炎、恶心/呕吐、腹泻及Ⅲ/Ⅳ级不良反应发生例数均多于观察组(P<0.05)。治疗前两组患者肠道各菌群数量差异无统计学意义(P>0.05);治疗后对照组患者乳杆菌、双歧杆菌数量及杆/球比明显少于观察组(P<0.01),而肠球菌、大肠埃希菌数量明显多于观察组(P<0.01)。治疗后对照组患者乳杆菌、双歧杆菌数量及杆/球比明显少于治疗前(P<0.01),而肠球菌、大肠埃希菌数量多于治疗前(P<0.05)。治疗后观察组患者乳杆菌、双歧杆菌数量及杆/球比多于治疗前(P<0.05);而肠球菌、大肠埃希菌数量与治疗前差异无统计学意义(P>0.05)。结论 BTVC对胃癌术后化疗副作用有预防作用,并可调节患者肠道菌群。 Objective To explore the effect of oral Bifid Triple Viable capsules(BTVC)on the side effects of chemotherapy and intestinal flora in patients with advanced gastric cancer after postoperative chemotherapy.Methods Patients with gastric cancer who were admitted in our hospital from February 2016 to January2017 and underwent first chemotherapy after radical gastrectomy were randomly divided into the control group(32 cases,accepting Oxaliplatin + S-1 chemotherapy)or the observation group(26 cases,accepting Oxaliplatin + Capecitabine+ BTVC treatment).The changes of intestinal flora and side effects in the two groups were observed.Results After treatment,the counts of WBC( 3×109/L),granulocytes( 2×109/L),hemoglobin( 110 g/L)and platelet( 100×109/L),the incidences of liver function damage,peripheral neuritis,nausea,vomiting and diarrhea as well as grade Ⅲ/Ⅳ adverse reactions in the control group were more than in the observation group(P〈0.05).Before treatment,there was no significant difference in the numbers of intestinal bacteria between the two groups(P〉0.05).After treatment,the numbers of Lactobacilli and Bifidobacteria and the ratio of bacilli/enterococci(B/E)in the control group were significantly less(P〈0.01),while those of Enterococci and Escherichia coli were significantly more than in the observation group(P〈0.01).After treatment,the numbers of Lactobacilli and Bifidobacteria and the B/E ratio significantly reduced(P〈0.01),while the numbers of Escherichia coli and Enterococci increased(P〈0.05).After treatment,the numbers of Lactobacilli and Bifidobacteriaand the B/E ratio in the observation group increased(P〈0.05),but the numbers of Escherichia coli and Enterococci did not change significantly(P〉0.05).Conclusion BTVC can prevent the side effects of chemotherapy after gastric cancer operation and regulate the intestinal flora.
作者 程康文 左伯海 王贵和 束宽山 郑明 王振兴 CHENG Kangwen;ZUO Bohai;WANG Guihe;SHU Kuanshan;ZHENG Ming;WANG Zhenxing(Department of Gastrointestinal Surgery, Tongling Peoplels Hospital, Tongling, Anhui 244000, Chin)
出处 《中国微生态学杂志》 CAS CSCD 2018年第6期667-672,共6页 Chinese Journal of Microecology
基金 安徽省铜陵市卫生科研项目(卫科研[2015]12号)
关键词 双歧三联活菌胶囊 胃肿瘤 化疗副作用 肠道菌群 Bifid Triple Viable capsule Stomach tumor Side effects of chemotherapy Intestinal flora
  • 相关文献

参考文献8

二级参考文献125

  • 1刘淑英,王晓稼.贝伐单抗在肿瘤治疗中相关毒副反应[J].肿瘤学杂志,2009,15(12):1133-1135. 被引量:3
  • 2胡大一,刘梅林,郭艺芳.老年高血压的诊断与治疗中国专家共识(2011版)[J].中国医学前沿杂志(电子版),2012,4(2):31-39. 被引量:101
  • 3Persiani R,DUgo D,Rausei S,et al.Prognostic indicators in locallyadvanced gastric cancer(LAGC)treated with preoperative chemotherapyAnd D2-gastrectomy[J].J Surg Oncol,2005,89(4):227-236.
  • 4Bentrem D,Wilton A,Mazumdar M,et al.The value of peritonealcytology as a preoperative predictor in patients with gastric carcinomaundergoing a curative resection[J].Ann Surg Oncol,2005,12(5):347-353.
  • 5Ajani JA,Mansfield PF,Janjan N,et al.Multi-institutional trial ofpreopcratlve chemoradiotherapy in patients with potentiallyrespactable gastric carcinonm [J].J Clin Oncol,2004,22(14):2774.
  • 6Paoletti X,Oba K,Burzykowski T,et al.Benefit of adjuvant chemotherapyfor resectable gastric cancer: a meta-analysis [J].JAMA,2010,303(17):1729-1737.
  • 7Bang YJ,Kim YW.Adjuvant capecitabine and oxaliplatin forgastric cancer after D2 gastrectomy (CLASSIC):a phase 3open-label,randomised controlled trial[J].Lancet,2012,379(9813): 315-321.
  • 8Sakuramoto S,Sasako M.Adjuvant chemotherapy for gastric cancerwith S-1,an oral fluoropyrimidine[J].N Engl J Med,2007,357(18): 1810-1820 .
  • 9Koizumi W,Narahara H,Hara T,et al.S-l plus cisplatin versusS-1 alone for first-line treatment of advanced gastric cancer(SPIRITS tria1):a phase llI trial[J].Lancet Oncol,2008,9(3):215-221.
  • 10Daisuke Takahari,Yasushi Rino.Survival analysis of adjuvantchemotherapy with S-1 plus cisplatin for stage Ⅲ gastric cancer[J].Surg Today,2014,(14):11-21.

共引文献429

同被引文献307

引证文献26

二级引证文献150

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部